Inctye’s Pemazyre authorised in the EU for bile duct cancer
Kinase inhibitor authorised to treat advanced bile duct cancer patients with a FGFR2 fusion or rearrangement
Read More
Tag: pemazyre
US clears first targeted treatment for cholangiocarcinoma
Incyte’s Pemazyre can now be used to treat the bile duct cancer. The firm has also launched a global COVID-19 trial
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
